CION Ameerpet
Marginal zone lymphoma is a slow-growing B-cell non-Hodgkin lymphoma with three distinct subtypes. This guide explains what it is, why an underlying infection can matter, and how CION's haematology-oncology team plans care.
Marginal zone lymphoma (MZL) is a group of slow-growing (indolent) B-cell non-Hodgkin lymphomas. It begins in the "marginal zone" — the outer rim of a lymphoid follicle, where mature B-cells sit. Because it grows slowly, MZL is often a long-term, manageable condition, and many people live with it for years. It is one of several indolent lymphomas alongside follicular lymphoma.
What makes MZL distinctive is its close link to chronic immune stimulation — long-standing infection or inflammation. In some cases, treating that underlying cause can control the lymphoma itself. There are three subtypes, and telling them apart matters because they are monitored and treated differently.
This page explains the subtypes, the causes, symptoms, how MZL is diagnosed and treated, and the outlook. For the wider picture of lymphoma care, see our Lymphoma hub and the Lymphoma Treatment in Hyderabad page, or meet the best lymphoma doctors in Hyderabad.
Marginal zone lymphoma is one of the few cancers that can sometimes be treated by clearing an infection. In localised gastric MALT lymphoma driven by Helicobacter pylori, antibiotic therapy to eradicate the bacterium can make the lymphoma regress in a large proportion of patients — so infection testing is a standard first step. (Source: NCCN and ESMO B-cell lymphoma guidelines.)
MZL is divided into three subtypes that look similar under the microscope but arise in different places and behave differently. Knowing the exact subtype — confirmed on tissue — is what lets the team tailor care.
The most common subtype. It starts in mucosa-associated lymphoid tissue outside the lymph nodes — most often the stomach, but also the salivary glands, lung, thyroid or eye. Gastric MALT is closely linked to H. pylori infection. Read more on our dedicated MALT lymphoma & the H. pylori link page.
Splenic marginal zone lymphoma mainly involves the spleen and bone marrow, often with a raised lymphocyte count in the blood and sometimes low blood counts. It has been associated with chronic hepatitis C infection in some patients, so testing for this is part of the work-up.
Nodal marginal zone lymphoma is centred on the lymph nodes, without the extranodal or splenic pattern. It usually shows as painless swollen nodes. It shares many features with the other subtypes but is managed as nodal disease, similar in some respects to small lymphocytic lymphoma.
MZL is an indolent B-cell lymphoma — quite different from aggressive types such as diffuse large B-cell lymphoma (DLBCL). Rarely, an indolent MZL can transform into a faster-growing lymphoma over time, which is why ongoing monitoring matters.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just diagnosed with marginal zone lymphoma, want to understand your subtype, or need a second opinion before treatment? CION's haematology-oncology team is here.
MZL is strongly linked to chronic immune stimulation — the immune system being kept switched on for years by an infection or inflammation. Recognised associations include H. pylori (gastric MALT lymphoma), chronic hepatitis C (splenic marginal zone lymphoma in some patients), and autoimmune conditions such as Sjögren's syndrome and Hashimoto's thyroiditis (MALT lymphoma of the salivary glands and thyroid). Identifying a treatable cause can change the whole plan.
Because MZL grows slowly, many people have few or no symptoms and it is sometimes found by chance. When symptoms occur, they track the subtype:
These signs have many ordinary causes. But swelling or abdominal fullness that is new, persistent and not settling should be checked. Speak to a CION lymphoma specialist if you have these signs or a confirmed MZL diagnosis.
Confirming MZL — and pinning down its subtype — takes a step-by-step pathway. CION delivers biopsy coordination, bone-marrow examination, molecular testing and staging directly, and every case is reviewed by a multidisciplinary tumour board.
Diagnosis needs a tissue sample — from an affected lymph node, the involved organ (for gastric MALT lymphoma, often an endoscopic biopsy of the stomach), or bone marrow for suspected splenic disease. A haematopathologist examines the cells and runs immunohistochemistry, which typically shows a mature B-cell pattern (CD20-positive) without the markers that define other lymphomas such as mantle cell lymphoma.
A bone-marrow examination and blood tests help assess spleen and marrow involvement — especially important in splenic marginal zone lymphoma, where the lymphocyte count is often raised. Testing for H. pylori and hepatitis C is done where relevant, because a positive result can open up a treatable cause.
Imaging — often a PET-CT or CT scan — maps how widespread the disease is and whether it is localised or more diffuse. This staging information, alongside the subtype and your symptoms, guides the treatment decision. Detailed staging and PET-CT are explained on our Lymphoma Treatment in Hyderabad page.
A large share of people with indolent lymphomas like MZL do not need treatment the moment they are diagnosed. For symptom-free, low-volume disease, guidelines support active monitoring ("watch-and-wait") — starting treatment only when the lymphoma causes symptoms or grows. This spares people the side effects of therapy while the disease is stable, with a clear plan to step in if things change. (Source: NCCN and ESMO indolent B-cell lymphoma guidelines.)
Treatment depends on the subtype, how widespread the disease is, and whether it is causing symptoms. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. The main approaches are:
For localised gastric MALT lymphoma driven by H. pylori, the first step is often antibiotic therapy to clear the infection, which can make the lymphoma regress. Where a splenic MZL is linked to hepatitis C, treating that infection may also help control the disease. This "treat-the-cause" approach is what makes MZL distinctive.
Localised MALT lymphoma that is not infection-driven — or that persists after treating the infection — is often treated with targeted radiation therapy (IMRT), which CION delivers directly. Modern radiation shapes the dose precisely to the affected area while sparing healthy tissue.
For symptomatic splenic or nodal disease, or more widespread MALT lymphoma, options include an anti-CD20 monoclonal antibody — given alone or combined with chemotherapy — and targeted therapy. CION's medical oncology team delivers antibody, chemotherapy and targeted therapy in-house. Specific drug regimens are individualised on the Lymphoma Treatment in Hyderabad page. If disease is more advanced and a stem-cell transplant is ever considered, CION coordinates that step through accredited partner facilities.
Many people with symptom-free, low-volume MZL are safely monitored with regular reviews rather than treated straight away — a standard, evidence-based approach for indolent lymphoma. For tips on coping well with slow-growing disease, see living with an indolent lymphoma.
Marginal zone lymphoma is one of the more favourable non-Hodgkin lymphomas. As an indolent disease it is often controlled for many years, and published series report long survival for most patients — though outcomes vary by individual, subtype, stage and response to treatment. It is best thought of as a chronic, manageable condition; some localised MALT lymphomas cleared of H. pylori achieve lasting remission. A small proportion can transform into a faster-growing lymphoma over time, so ongoing monitoring is important. (Figures follow NCCN and ESMO guidance and are general, not personal predictions.)
A second opinion is especially valuable if:
CION offers a dedicated, free written second-opinion service, delivered by the best lymphoma doctors in Hyderabad at the best lymphoma hospital in Hyderabad. You deserve a plan built around healing, not billing, with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma team — especially valuable if your MZL subtype is unclear or infection testing has not yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Marginal zone lymphoma (MZL) is a group of slow-growing (indolent) B-cell non-Hodgkin lymphomas that begin in the "marginal zone" — the outer rim of a lymphoid follicle where mature B-cells live. There are three main subtypes: extranodal marginal zone lymphoma (also called MALT lymphoma, which starts in tissue outside the lymph nodes such as the stomach), splenic marginal zone lymphoma (centred on the spleen), and nodal marginal zone lymphoma (centred on the lymph nodes). Most people with MZL live for many years, and some subtypes respond to treating an underlying infection. Care is planned by CION's haematology-oncology team — see our lymphoma hub for the full picture.
MZL is divided into three subtypes that behave differently. Extranodal MZL (MALT lymphoma) is the most common and starts in mucosa-associated tissue — most often the stomach, but also the salivary glands, lung, thyroid or eye. Splenic marginal zone lymphoma mainly involves the spleen and bone marrow, often with a high lymphocyte count and sometimes a link to hepatitis C. Nodal marginal zone lymphoma involves the lymph nodes and looks similar under the microscope but without the extranodal or splenic pattern. Distinguishing the three matters because it changes how the lymphoma is monitored and treated. Read more about the gastric form on our MALT lymphoma page.
Marginal zone lymphoma is strongly linked to chronic immune stimulation — long-standing infection or inflammation that keeps B-cells activated. The clearest example is Helicobacter pylori, the stomach bacterium behind most gastric MALT lymphomas. Splenic marginal zone lymphoma has been associated with chronic hepatitis C infection in some patients. Autoimmune conditions such as Sjögren's syndrome and Hashimoto's thyroiditis raise the risk of MALT lymphoma in the salivary glands and thyroid. This infection-and-inflammation link is important because, in selected cases, treating the underlying cause can control the lymphoma. Per NCCN and ESMO guidance, testing for these associations is part of the standard work-up.
Because MZL is slow-growing, many people have few or no symptoms and it is sometimes found by chance. When symptoms occur they depend on the subtype. Splenic marginal zone lymphoma often causes an enlarged spleen, giving fullness or discomfort in the upper-left abdomen, sometimes with a high lymphocyte count or low blood counts. Nodal marginal zone disease usually shows as painless swollen lymph nodes. Extranodal MALT lymphoma causes symptoms in the organ involved — indigestion or stomach discomfort for gastric MALT, a dry or swollen salivary gland, and so on. So-called "B symptoms" — drenching night sweats, unexplained fever and weight loss — are less common in indolent lymphoma but should always be reported. Speak to a CION specialist if you have persistent swelling or abdominal fullness.
Diagnosis needs a tissue biopsy — of an affected lymph node, the involved organ (for MALT lymphoma, often an endoscopic biopsy of the stomach), or a bone-marrow sample for suspected splenic disease. A haematopathologist examines the cells and runs immunohistochemistry, which typically shows a mature B-cell pattern (CD20-positive) without markers of other lymphomas. A bone-marrow examination and blood tests help assess spleen and marrow involvement, and tests for H. pylori and hepatitis C are done where relevant. Imaging — often a PET-CT or CT scan — maps how widespread the disease is. CION delivers biopsy coordination, bone-marrow examination, molecular testing and staging directly, and every case is reviewed by a multidisciplinary lymphoma tumour board.
Treatment depends on the subtype, how widespread the disease is, and whether it is causing symptoms. For localised gastric MALT lymphoma linked to H. pylori, the first step is often antibiotic therapy to clear the infection, which can make the lymphoma regress. Localised MALT lymphoma elsewhere may be treated with targeted radiation therapy (IMRT), which CION delivers directly. For symptomatic splenic or nodal disease, options include an anti-CD20 monoclonal antibody, given alone or with chemotherapy, and targeted therapy — all delivered in-house by CION's medical oncology team. Many people with symptom-free, low-volume MZL are safely monitored with watch-and-wait. Specific drug regimens are individualised on our Lymphoma Treatment in Hyderabad page.
Marginal zone lymphoma is one of the more favourable non-Hodgkin lymphomas. As an indolent (slow-growing) disease, it is often controlled for many years, and published series report long survival for most patients — though figures vary by individual, subtype, stage and response to treatment. It is generally regarded as a chronic, manageable condition rather than one with a single "cure" point; some localised MALT lymphomas cleared of H. pylori can achieve lasting remission. A small proportion can transform into a faster-growing lymphoma over time, so ongoing monitoring matters. For living well with slow-growing disease, see living with an indolent lymphoma. Outlook estimates here follow NCCN and ESMO guidance and are general, not personal predictions.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.